EVENT DATE: JUNE 9-10, 2018 (Now Fully Accredited)
Cardiovascular disease is a global health problem with no geographic, gender, or socio-economic boundaries. Despite the tremendous advances in cardiac care made recently, including drugs, devices, and diagnostic innovations, many patients continue to die from heart disease or live with significant morbidity. Challenges for the next decade include health promotion and disease prevention, obesity and diabetes, and acute heart failure and cardiorenal disease. We must broaden our scope of intervention to emphasize and extend preventive strategies, and translate our innovations into affirmative actions through carefully designed health policy strategies. Artifi cial intelligence, along with genomic and proteomic biomarkers, promise to improve early detection and risk stratification, leading to a more personalized approach to cardiovascular medicine.
This year, our conference is joined with the International Symposium on Atherosclerosis (http://www.isa2018.org).
The joint program brings together the most exciting advances in cardiovascular disease and related cardiometabolic and cardiorenal medicine, from treatment to prevention and innovation to application. The program is unique because of its translational theme. The global faculty and participating audience represent the faces of cardiovascular medicine with a truly international perspective.
To enhance the learning experience, the symposium features lectures, panel discussions, problem-solving sessions, and case presentations to foster interaction between the faculty and participants. The case-based presentations will be particularly valuable in translating theoretical concepts and guidelines, to practice.